A Qualitative Exploration of the National Institute for Health and Care Excellence's Impact on International Health Technology Assessment

Author(s)

ABSTRACT WITHDRAWN

OBJECTIVES:

This research aimed to investigate the impact of NICE methodology and decisions on other international HTA bodies. We sought to identify direct and indirect factors that may influence an international HTA body's methods or outcomes. To the best of our knowledge, this is the first research to use a qualitative approach to understand the influence of NICE on other HTA bodies.

METHODS:

We conducted thirteen semi-structured qualitative interviews with HTA/market access experts from industry and academia representing nine countries (Brazil, Italy, Israel, Japan, Poland, Saudi Arabia, Sweden, and United Arab Emirates). The interview script was organized into three main sections: comparing NICE methods and processes with other HTA bodies, the impact of specific NICE decisions and Likert scale questions (to allow for comparability of opinions).

RESULTS:

Most interviewees believed their local HTA body would consider NICE's decision when evaluating a medicine. However, the way and extent to which NICE influences HTA varied across countries. The most common means of considering a NICE decision was as background information/context for an HTA evaluation. Generally, interviewees suggested that negative NICE decisions had more impact on local decision-making than positive decisions. 9 out of 13 interviewees agreed or strongly agreed that their country’s HTA body considers the decisions of other HTA bodies in their decision-making process. 11 out of 13 interviewees agreed or strongly agreed that the development of their country’s HTA body methods and processes were influenced by NICE.

CONCLUSIONS:

NICE is perceived to be a seminal HTA body, with continued influence on HTA bodies in other countries. However, the mechanisms and extent of influence vary considerably between countries. We suggest that implicit factors are likely to contribute more to NICE's influence compared to individual decisions. Nevertheless, further research is needed to reveal these factors and increase efficiency in international HTA decision-making processes.

Conference/Value in Health Info

2023-05, ISPOR 2023, Boston, MA, USA

Value in Health, Volume 26, Issue 6, S2 (June 2023)

Code

HTA94

Topic

Health Policy & Regulatory, Health Technology Assessment

Topic Subcategory

Decision & Deliberative Processes, Reimbursement & Access Policy, Systems & Structure

Disease

No Additional Disease & Conditions/Specialized Treatment Areas

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×